Ischemic Stroke Clinical Trial
— EPICS-PilotOfficial title:
European Blood Pressure Intensive Control After Stroke - Pilot Trial
Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack. However, the optimal target blood pressure after a person suffers a stroke is not known. This is a study designed to establish the feasibility of a larger clinical trial, the aim of which will be to find out if greater blood pressure lowering is safe and effective for patients who suffer a stroke.
Status | Not yet recruiting |
Enrollment | 122 |
Est. completion date | September 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: 1. Age =40 2. Ischaemic stroke, proven by imaging (including transient ischaemic attack with imaging evidence of acute brain ischaemia 3. Living at home and independent (walking without the aid of another person, but may have some help for daily activities - equivalent to Rankin score 3 or less) 4. SBP=130mmHg at entry (average of 2 measures, seated, after resting alone in office for 5 minutes) 5. Qualifying Stroke/TIA between 7 days and 1 year of randomization 6. Glomerular filtration rate (eGFR) greater than or equal to 50 ml/min/m2 7. Medically-stable and capable of participating in a randomised trial, including home BP measures, in the opinion of the study physician 8. Willing to provide informed consent (no surrogate consent will apply) Exclusion Criteria: 1. Stroke/TIA due to cardio-embolism or other defined causes (eg. dissection, endocarditis, other specified) 2. Severe stenosis of large cranio-cervical artery (>70% stenosis of cervical carotid, vertebral, or Circle of Willis artery) 3. Medical history of primary intracerebral haemorrhage (asymptomatic cerebral microbleeds detected on brain MRI are not excluded) 4. SBP <110mmHg after 3 minutes of standing or other contra-indication to intensive SBP lowering in opinion of treating clinician* (eg. syncope or pre-syncope, recurrent falls) 5. Unlikely to comply with study procedures (home BP measures, follow-up visits) due to severe or fatal co-morbid illness (eg. dementia, active malignancy, severe frailty) or other factor (eg. inability to travel) 6. Women of child-bearing potential |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University College Dublin | Attikon Hospital, Cork University Hospital, Hospital Universitario La Paz, HRB Stroke Trials Network Ireland, Mater Misericordiae University Hospital, National University of Ireland, Galway, Ireland, Newcastle University, St Vincent's University Hospital, Ireland, Tallaght University Hospital, Universitaire Ziekenhuizen Leuven, University Hospital Waterford, University of Calgary, University of Limerick, University of Oslo |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of patients who do not complete the study due to tolerability or other issues | Patients who are not retained in the study will give an insight into anticipated retention in the Phase 3 trial and sample size considerations. | 18 months (or end of trial visit) | |
Other | Ability of sites to rapidly identify eligible patients from clinics and stroke units | The inclusion of prevalent cases already attending stroke clinics or discharged from stroke units within the last year is an important design feature, aimed to rapidly accrue patients into the trial and thus to maximise the duration of follow-up within the terms allowed by funders. This outcome will be judged on the basis of qualitative feedback from participating sites. | 18 months (or end of trial visit) | |
Other | Feasibility of home blood pressure (BP) measures and diary entries | This outcome will be judged on the basis of qualitative feedback from participants and the the proportions of participants adhering to the use of home blood pressure diaries. | 18 months (or end of trial visit) | |
Other | Feasibility of remote (phone/video) visits | The feasibility of remote (phone/video) visits will be assessed by the proportion of patients adhering to participation in remote visit consultations | 18 months (or end of trial visit) | |
Primary | Difference in achieved SBP | The difference in mean SBP in the intensive versus control groups, at 18 months (or end-of-trial visit) | 18 months (or end of trial visit) | |
Secondary | Time to first composite major vascular event | Defined as recurrent stroke, myocardial infarction, cardiac arrest, and to each component of the composite, stratified as fatal, non-fatal and total. | 18 months (or end of trial visit) | |
Secondary | Proportions of patients assigned to target goals successfully reaching target | 18 months (or end of trial visit) | ||
Secondary | All-cause death | Time to all-cause death | 18 months (or end of trial visit) | |
Secondary | Number of dose-titrations required | 18 months (or end of trial visit) | ||
Secondary | Time in target range | Proportion of SBP measures in the assigned target during trial participation | 18 months (or end of trial visit) | |
Secondary | Loss to follow-up | Number of participants lost to follow-up in both treatment arms | 18 months (or end of trial visit) | |
Secondary | Time taken to reach target range | 18 months (or end of trial visit) | ||
Secondary | Change in cognition | Change in Montreal cognitive assessment score (range 0-30) at last follow-up compared with baseline score. A lower score indicates greater cognitive impairment. | 18 months (or end of trial visit) | |
Secondary | Quality of life score | Change in EQ5D-5L score (5 domains assessed with scores of 1-5 ranking the severity of impairment, with higher scores indicating poorer quality of life) at last follow-up compared with baseline | 18 months (or end of trial visit) | |
Secondary | Difference in mean achieved diastolic blood pressure (DBP) between groups | 18 months (or end of trial visit) | ||
Secondary | Change in SBP and DBP from baseline to end-of-trial | 18 months (or end of trial visit) | ||
Secondary | Time required per follow up visit | 18 months (or end of trial visit) | ||
Secondary | Feasibility of remote BP titration | Qualitative feedback from patients on their views relating to the feasibility of home blood pressure monitoring and remote dose titration will be sought. This design feature will be carefully examined in the pilot, before incorporation into the main trial. | 18 months (or end of trial visit) | |
Secondary | Disability in intensive-SBP and guideline-based SBP target patients assessed by modified Rankin score (shift analysis and proportion with no, mild, or moderate disability, Rankin score 0-3) | Proportion of participants with disability. The modified Rankin scale is graded from 0-6, with 0 indicating no disability and 6 indicating death. | 18 months (or end of trial visit) | |
Secondary | Number of adverse events, serious adverse events, and suspected unexpected serious adverse reactions (SUSARs) | Difference in proportion of patients with adverse events, serious adverse events and SUSARS | 18 months (or end of trial visit) | |
Secondary | Number of pre-specified adverse events | 18 months (or end of trial visit) | ||
Secondary | Qualitative patient feedback obtained via workshops and questionnaires | 18 months (or end of trial visit) | ||
Secondary | Total, direct and indirect (eg. via lost income to study participants or family members) costs associated with face-to-face visits for study participants will be quantified | 18 months (or end of trial visit) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02924168 -
Radial Shock Waves for Functional Disability in Stroke
|
N/A |